Cerevance

91 articles about Cerevance

• Cerevance Presents at 35th Symposium on Medicinal Chemistry in Eastern England

  4/17/2024

  Cerevance today announced plans to deliver an oral presentation at the upcoming 35th Symposium on Medicinal Chemistry, taking place in Hatfield, United Kingdom April 25, 2024.

• Cerevance to Participate at the 23rd Annual Needham Virtual Health Care Conference

  4/2/2024

  Cerevance today announced participation at the upcoming 23rd Annual Needham Virtual Health Care Conference. The event takes place from April 8-11, 2024.

• Cerevance Announces Presentation at Alzheimer’s Research UK Conference

  3/13/2024

  Cerevance today announced plans to present a poster at the upcoming Alzheimer’s Research UK Conference, taking place in Liverpool, United Kingdom, March 20-21, 2024.

• Cerevance Announces Presentation at AD/PD™ 2024 International Conference

  2/27/2024

  Cerevance today announced plans to present a virtual and onsite poster at the upcoming AD/PD™ 2024 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders, taking place in Lisbon, Portugal from March 5-9, 2024.

• Cerevance to Participate at the TD Cowen 44th Annual Health Care Conference

  2/22/2024

  Cerevance today announced participation at the upcoming TD Cowen 44th Annual Health Care Conference, taking place at the Boston Marriott Copley Place in Boston, MA from March 4-6, 2024. Company management will host one-on-one meetings during the conference.

• 

  Neuroinflammation: The Natural Next Alzheimer’s Target?

  2/5/2024

  Biotech companies are exploring multiple targets in the fight against neuroinflammation. Experts say these projects could yield the next breakthrough in treating Alzheimer’s disease.

• Cerevance to Participate in Fireside Chat at the 2023 RBC Capital Markets Healthcare Private Company Virtual Conference

  12/5/2023

  Cerevance announced that chief executive officer, Craig Thompson, will participate in a fireside chat and host investor meetings at the RBC Capital Markets Healthcare Private Company Conference.

• Cerevance Announces Presentation at the 34th International Symposium on ALS/MND

  11/28/2023

  Cerevance announced a poster presentation at the 34th International Symposium on ALS/MND, taking place in Basel, Switzerland from December 6 – 8, 2023.

• Cerevance Doses First Patient in ASCEND Phase 2 Clinical Study of CVN424, a First-in-Class, Non-Dopaminergic Therapy for the Treatment of Parkinson’s Disease

  11/13/2023

  Cerevance today announced that the first subject has been dosed in the Phase 2 clinical study of CVN424 in individuals with early-stage Parkinson’s disease.

• Cerevance Announces Presentation at the SFN Neuroscience 2023 Annual Meeting

  11/7/2023

  Cerevance today announced plans to present a poster presentation at the Neuroscience 2023 Annual Meeting presented by the Society for Neuroscience, taking place in Washington, D.C., November 11 – 15th, 2023.

• Cerevance to Participate at the Wells Fargo 2023 Private Biotech Symposium

  10/25/2023

  Cerevance, a private, clinical-stage drug discovery and development company focused on developing precision novel therapeutics for central nervous system (CNS) diseases using the company’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform, today announced participation at the upcoming Wells Fargo 2023 Private Biotech Symposium, taking place virtually on November 1, 2023.

• Cerevance to Participate at the Leerink Biopharma Private Company Connect

  10/18/2023

  Cerevance, a private, clinical-stage drug discovery and development company focused on developing precision novel therapeutics for central nervous system diseases using the company’s proprietary Nuclear Enriched Transcript Sort sequencing platform, announced participation at the upcoming Leerink Biopharma Private Company Connect, taking place virtually from October 25 – 26, 2023.

• Cerevance to Participate at the 3rd Annual Needham Biotech Private Company Forum

  10/10/2023

  Cerevance today announced participation at the upcoming 3rd Annual Needham Biotech Private Company Forum, taking place virtually from October 17 – 18, 2023.

• Cerevance to Participate at the 2023 Life Sciences Private Company Showcase

  10/4/2023

  Cerevance today announced that Craig Thompson, chief executive officer of Cerevance, will present and host investor meetings at the upcoming 2023 Life Sciences Private Company Showcase.

• Cerevance Announces Presentation at the 36th European College of Neuropsychopharmacology Congress

  10/2/2023

  Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel precision therapeutics for central nervous system (CNS) diseases using the company’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform, today announced a poster presentation at the 36th European College of Neuropsychopharmacology Congress (ECNP), taking place in Barcelona, Spain from October 7 – 10, 2023.

• Cerevance Doses First Subject in Phase 1 Clinical Study of CVN293, a Selective Inhibitor of KCNK13 Designed to Selectively Modulate Neuroinflammation, for the Treatment of ALS and Alzheimer’s Disease

  9/19/2023

  Cerevance, today announced that the first subject has been dosed in the Phase 1 clinical study evaluating the safety, tolerability, and pharmacokinetics of CVN293.

• Cerevance to Present During the 6th Annual LSX World Congress USA

  9/6/2023

  Cerevance today announced Craig Thompson, chief executive officer (CEO) and Johnna Simões, vice president, corporate development, will participate in panel discussions during the 6th Annual LSX World Congress USA being held in Boston, MA, September 13-14th.

• Cerevance Announces Presentation at the 22nd Society of Chemical Industry / Royal Society of Chemistry Medicinal Chemistry Symposium

  8/31/2023

  Cerevance today announced plans to present an oral presentation at the upcoming 22nd Society of Chemical Industry / Royal Society of Chemistry Medicinal Chemistry Symposium, taking place in Cambridge, United Kingdom, September 10 – 13th, 2023.

• Fierce Biotech Names Cerevance a “Fierce 15” Biotech Company of 2023

  8/28/2023

  Cerevance has been named by Fierce Biotech as one of the most promising early-stage biotechnology companies in the industry in 2023, showcased on this year’s Fierce 15 list.

• Cerevance Announces Presentation at the Alzheimer’s Association International Conference

  7/10/2023

  Cerevance today announced plans to present a poster presentation at the upcoming Alzheimer’s Association International Conference (AAIC), taking place in Amsterdam, Netherlands, July 16 – 20, 2023.